“For any surgeon, there is no greater satisfaction than seeing an innovation move beyond concept” – Fraser Sutherland, CardioPrecision
A Glasgow medical tech firm behind a robotic surgery platform has hailed a breakthrough in the key US healthcare market.
CardioPrecision, which was originally spun out of the NHS through InnoScot Health, announced last year that its tech for robotic-assisted transcervical aortic valve replacement (AVR) procedures had been successfully extended to patients, with the promise of greater precision, less pain and faster recovery times.
Now, the firm’s groundbreaking approach has delivered another first, at the Cleveland Clinic in Ohio, after being adopted stateside into routine clinical use.
Fraser Sutherland, consultant cardiac surgeon and chief medical officer of CardioPrecision, said: “I am proud to see transcervical robotic AVR become part of the routine robotic cardiac surgery programme at the Cleveland Clinic.
“Having been involved in the development of this technology from the beginning, one of the most rewarding aspects is seeing the original vision translate into tangible patient benefits. For any surgeon, there is no greater satisfaction than seeing an innovation move beyond concept and begin improving the recovery experience of patients in routine clinical practice.”
The company has taken major steps into the high value US market in recent years and achieved domestic success with its cutting-edge technologies adopted by 75 per cent of cardiac centres in Scotland.
The global robotic-assisted surgery market is currently thought to be worth around £13 billion and is projected to rise to around £34bn by 2033.
Executive chair of InnoScot Health, Graham Watson, said: “We are proud to be part of the CardioPrecision journey and congratulate them on their latest milestone in robotic-assisted aortic valve replacement.
“Medtech innovations have to overcome many challenges in order to successfully be integrated into routine use, thereby ensuring that patients consistently receive the safest, most effective, and highest-quality care available, so the significance of this adoption is clear.”
Sutherland recently attended the Cleveland Clinic’s state-of-the-art robotics in cardiac and thoracic surgery course, adding: “It was particularly encouraging to see robotic aortic valve replacement receive increasing attention throughout the programme. Transcervical AVR using CoreVista System from CardioPrecision was featured in presentations that highlighted positive clinical outcomes and patient recovery experiences.”